Mobile website
Clinical Research
Efficacy and safety of erlotinib combined with albumin-bound paclitaxel and carboplatin in the treatment of NSCLC patients
- Article
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
Abstract:
[Abstract] Objective: To evaluate the clinical efficacy and safety of erlotinib combined with albumin-bound paclitaxel and carboplatin in the treatment of patients with EGFR-mutation positive non-small cell lung cancer (NSCLC). Methods: A total of 80 patients with EGFR-mutation positive NSCLC treated at the Department of Oncology, Xijing Hospital from May 2019 to June 2021 were retrospectively selected for this study. According to their treatment methods, the patients were divided into two groups: the study group (n = 38) and the control group (n = 42). Both groups received erlotinib targeted therapy, while the study group also received combination chemotherapy with albumin-bound paclitaxel and carboplatin. The treatment efficacy [objective response rate (ORR), disease control rate (DCR)], immune function [CD3+ , CD4+ , CD8+ , CD4+ /CD8+ , natural killer (NK) cells], survival status [3-years survival rate, overall survival (OS), progression-free survival (PFS), Karnofsky performance status (KPS) score], levels of tumor markers [carcinoembryonic antigen (CEA), cytokeratin fragment 19 (CYFRA21-1), vascular endothelial growth factor (VEGF)], and the incidence of adverse reactions were compared between the two groups. Results: The DCR in the study group was significantly higher than that in control group (89.47% vs 42.86%) (P < 0.05). The ORR in the study group was also higher than that in control group (36.84% vs 23.81%), but the difference was not statistically significant (P > 0.05). After treatment, the study group showed significantly higher levels of CD3+ , CD4+ , NK cells and CD4+ /CD8+ ratio, and lower levels of CD8+ compared to the control group (all P < 0.05). There was no significant difference in 3-years survival rate between the two groups (P > 0.05). However, the OS and PFS of the study group were longer than those of the control group (both P < 0.05), and the KPS score was higher (P < 0.05). The levels of CEA, CYFRA21-1 and VEGF in the study group were lower than those in control group (P < 0.05). The incidence of bone marrow suppression was higher in the study group than in control group (P < 0.05). Conclusion: Erlotinib targeted therapy combined with albumin-bound paclitaxel and carboplatin demonstrates good clinical efficacy in treating EGFR-mutation positive NSCLC. It reduces immune function damage, prolongs PFS in advanced NSCLC patients, and improves their quality of life, with a good safety profile.
Keywords:
non-small cell lung cancer ; immune function ; progression-free survival ; erlotinib ; albumin paclitaxel
